Approval is based on results from the Phase 3 KEYNOTE-A39 trial, which demonstrated a superior overall survival benefit with KEYTRUDA plus Padcev versus platinum-based chemotherapy (gemcitabine plus cisplatin or carboplatin) in these patientsApproval expands the use of KEYTRUDA plus Padcev for locally advanced or me.
Merck s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Merck (MRK) Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.